LAVA Therapeutics N.V. Reports Shareholder Vote Matters
| Field | Detail |
|---|---|
| Company | Lava Therapeutics NV |
| Form Type | 8-K |
| Filed Date | Jun 13, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-vote, corporate-governance
TL;DR
LAVA Therapeutics shareholders voted on something important June 11th. Details to follow.
AI Summary
LAVA Therapeutics N.V. filed an 8-K on June 13, 2025, reporting on a submission of matters to a vote of security holders that occurred on June 11, 2025. The filing does not contain specific details about the vote itself, but indicates a corporate action was put before shareholders.
Why It Matters
This filing signals that LAVA Therapeutics N.V. has engaged its shareholders in a formal voting process, which could pertain to significant corporate decisions or governance changes.
Risk Assessment
Risk Level: low — The filing is a standard procedural report on a shareholder vote without immediate financial implications disclosed.
Key Players & Entities
- LAVA Therapeutics N.V. (company) — Registrant
- June 11, 2025 (date) — Date of earliest event reported
- June 13, 2025 (date) — Date of report
FAQ
What specific matters were submitted for a vote by LAVA Therapeutics N.V. security holders?
The filing does not specify the exact matters submitted for a vote, only that a submission of matters to a vote of security holders occurred on June 11, 2025.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on June 11, 2025.
What is the filing date of this 8-K report?
This 8-K report was filed on June 13, 2025.
What is the principal executive office address for LAVA Therapeutics N.V.?
The principal executive offices are located at Yalelaan 62, Utrecht, The Netherlands, 3584 CM.
What is the telephone number for LAVA Therapeutics N.V.?
The telephone number is +31 85 016 3100.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 13, 2025 regarding LAVA Therapeutics NV.